{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:27:53Z","timestamp":1789122473830,"version":"build-2803163510"},"reference-count":59,"publisher":"Bentham Science Publishers Ltd.","issue":"37","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Resistance to lenvatinib poses a serious threat to the therapy of patients\nwith Hepatocellular Carcinoma (HCC). The mechanism by which HCC develops resistance\nto lenvatinib is currently unknown.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The aim of this study was to identify key genes and pathways involved in lenvatinib\nresistance in HCC using bioinformatic analysis and experimental validation.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Differentially expressed genes (DEGs) were identified from the GSE186191 gene\nexpression profile, comparing HCC cell lines with lenvatinib-resistant HCC cell lines. Gene\nOntology and Kyoto Encyclopedia of Genes and Genomes analyses were then carried out using\nDAVID. A protein-protein interaction network was constructed to visualize DEGs and\nidentify hub genes. The expression and prognostic significance of these hub genes were further\nexamined. Additionally, genomic enrichment analysis (GSEA) was utilized to investigate\nthe potential functions of key genes. Following this, the presence of AHSG was validated\nin both the original Huh7 cells and the lenvatinib-resistant Huh7 (Huh7LR) cells resistant\nto lenvatinib through the utilization of quantitative real-time PCR (qRT-PCR).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>A total of 232 DEGs were identified between HCC cell lines and those that are resistant\nto lenvatinib. These DEGs were significantly associated with arrhythmogenic right\nventricular cardiomyopathy, hypertrophic cardiomyopathy, dilated cardiomyopathy, and\nmucin-type O-glycan biosynthesis. Three hub genes, including AHSG, C6, and ORM1,\nwere identified. The low expression of AHSG showed a poorer prognosis in HCC. GSEA\ndemonstrated a significant correlation between low AHSG expression and pathways involving\nfatty acid metabolism, ribosome function, glycine, serine, and threonine metabolism, peroxisome\nactivity, and bile acid biosynthesis. The expression of AHSG was notably reduced\nin Huh7LR cells (p = 0.006) compared to Huh7 cells.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Diminished AHSG expression is strongly associated with lenvatinib resistance\nin HCC, suggesting that it may have implications for developing effective strategies to overcome\nthis resistance.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0109298673329991241111111941","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T01:15:24Z","timestamp":1737508524000},"page":"8387-8399","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identification of Key Genes and Pathways in Lenvatinib-resistant Hepatocellular Carcinoma using Bioinformatic Analysis and Experimental Validation"],"prefix":"10.2174","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5765-3844","authenticated-orcid":true,"given":"Ming","family":"Yang","sequence":"first","affiliation":[{"name":"Hepato-Pancreato-Biliary Center, School of Clinical Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua\nUniversity, Beijing, 102218, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7989-7628","authenticated-orcid":true,"given":"ZhaoYue","family":"Wang","sequence":"additional","affiliation":[{"name":"Hepato-Pancreato-Biliary Center, School of Clinical Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua\nUniversity, Beijing, 102218, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0083-8869","authenticated-orcid":true,"given":"Riga","family":"Su","sequence":"additional","affiliation":[{"name":"Hepato-Pancreato-Biliary Center, School of Clinical Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua\nUniversity, Beijing, 102218, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5227-9643","authenticated-orcid":true,"given":"Dongbing","family":"Li","sequence":"additional","affiliation":[{"name":"Scientific Research Center, Beijing ChosenMed Clinical Laboratory\nCo., Ltd., Beijing, 100176, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6059-6251","authenticated-orcid":true,"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research\n(Ministry of Education\/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital\nand Institute, Beijing, 100142, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"Sung H.","year":"2021","unstructured":"Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2021,71(3),209-249","journal-title":"CA Cancer J Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"Yang J.D.","year":"2019","unstructured":"Yang J.D.; Hainaut P.; Gores G.J.; Amadou A.; Plymoth A.; Roberts L.R.; A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol  2019,16(10),589-604","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","volume":"15","author":"Llovet J.M.","year":"2018","unstructured":"Llovet J.M.; Montal R.; Sia D.; Finn R.S.; Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol  2018,15(10),599-616","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"e17295","DOI":"10.1016\/j.heliyon.2023.e17295","volume":"9","author":"Zhou S.","year":"2023","unstructured":"Zhou S.; Xu H.; Wei T.; Inhibition of stress proteins TRIB3 and STC2 potentiates sorafenib sensitivity in hepatocellular carcinoma. Heliyon  2023,9(6),e17295","journal-title":"Heliyon"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"Kudo M.","year":"2018","unstructured":"Kudo M.; Finn R.S.; Qin S.; Han K.H.; Ikeda K.; Piscaglia F.; Baron A.; Park J.W.; Han G.; Jassem J.; Blanc J.F.; Vogel A.; Komov D.; Evans T.R.J.; Lopez C.; Dutcus C.; Guo M.; Saito K.; Kraljevic S.; Tamai T.; Ren M.; Cheng A.L.; Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet  2018,391(10126),1163-1173","journal-title":"Lancet"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/hep.30337","volume":"69","author":"Flynn M.J.","year":"2019","unstructured":"Flynn M.J.; Sayed A.A.; Sharma R.; Siddique A.; Pinato D.J.; Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma. Hepatology  2019,69(5),2258-2270","journal-title":"Hepatology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.3390\/jpm12111788","volume":"12","author":"Rizzo A.","year":"2022","unstructured":"Rizzo A.; Ricci A.D.; Brandi G.; Trans-arterial chemoembolization plus systemic treatments for hepatocellular carcinoma: An update. J Pers Med  2022,12(11),1788","journal-title":"J Pers Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"11363","DOI":"10.3390\/ijms231911363","volume":"23","author":"Rizzo A.","year":"2022","unstructured":"Rizzo A.; Ricci A.D.; Challenges and future trends of hepatocellular carcinoma immunotherapy. Int J Mol Sci  2022,23(19),11363","journal-title":"Int J Mol Sci"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/17425255.2021.2029405","volume":"17","author":"Rizzo A.","year":"2021","unstructured":"Rizzo A.; Santoni M.; Mollica V.; Logullo F.; Rosellini M.; Marchetti A.; Faloppi L.; Battelli N.; Massari F.; Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: The MOUSEION-02 study. Expert Opin Drug Metab Toxicol  2021,17(12),1455-1466","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00520-023-08083-w","volume":"31","author":"Guven D.C.","year":"2023","unstructured":"Guven D.C.; Erul E.; Kaygusuz Y.; Akagunduz B.; Kilickap S.; De Luca R.; Rizzo A.; Immune checkpoint inhibitor-related hearing loss: A systematic review and analysis of individual patient data. Support Care Cancer  2023,31(12),624","journal-title":"Support Care Cancer"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/cancers16101835","volume":"16","author":"Sahin T.K.","year":"2024","unstructured":"Sahin T.K.; Rizzo A.; Aksoy S.; Guven D.C.; Prognostic significance of the royal marsden hospital (RMH) score in patients with cancer: Aa systematic review and meta-analysis. Cancers  2024,16(10),1835","journal-title":"Cancers"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1153991","DOI":"10.3389\/fphar.2023.1153991","volume":"14","author":"Bo W.","year":"2023","unstructured":"Bo W.; Chen Y.; Lenvatinib resistance mechanism and potential ways to conquer. Front Pharmacol  2023,14,1153991","journal-title":"Front Pharmacol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"100647","DOI":"10.1016\/j.esmoop.2022.100647","volume":"7","author":"Uehara Y.","year":"2022","unstructured":"Uehara Y.; Ikeda S.; Kim K.H.; Lim H.J.; Adashek J.J.; Persha H.E.; Okamura R.; Lee S.; Sicklick J.K.; Kato S.; Kurzrock R.; Targeting the FGF\/FGFR axis and its co-alteration allies. ESMO Open  2022,7(6),100647","journal-title":"ESMO Open"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000526976","volume":"101","author":"Muraishi N.","year":"2023","unstructured":"Muraishi N.; Kawamura Y.; Akuta N.; Shindoh J.; Matsumura M.; Okubo S.; Fujiyama S.; Hosaka T.; Saitoh S.; Sezaki H.; Suzuki F.; Suzuki Y.; Ikeda K.; Arase Y.; Hashimoto M.; Yasuda I.; Kumada H.; The impact of lenvatinib on tumor blood vessel shrinkage of hepatocellular carcinoma during treatment: An imaging-based analysis. Oncology  2023,101(2),134-144","journal-title":"Oncology"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"100669","DOI":"10.1016\/j.aohep.2022.100669","volume":"27","author":"Chen Z.","year":"2022","unstructured":"Chen Z.; Ma Y.; Guo Z.; Song D.; Chen Z.; Sun M.; Ubiquitin-specific protease 1 acts as an oncogene and promotes lenvatinib efficacy in hepatocellular carcinoma by stabilizing c-kit. Ann Hepatol  2022,27(2),100669","journal-title":"Ann Hepatol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"e000799","DOI":"10.1136\/esmoopen-2020-000799","volume":"5","author":"Hegde A.","year":"2020","unstructured":"Hegde A.; Andreev-Drakhlin A.Y.; Roszik J.; Huang L.; Liu S.; Hess K.; Cabanillas M.; Hu M.I.; Busaidy N.L.; Sherman S.I.; Dadu R.; Grubbs E.G.; Ali S.M.; Lee J.; Elamin Y.Y.; Simon G.R.; Blumenschein G.R.; Papadimitrakopoulou V.A.; Hong D.; Meric-Bernstam F.; Heymach J.; Subbiah V.; Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open  2020,5(5),e000799","journal-title":"ESMO Open"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"Motzer R.J.","year":"2015","unstructured":"Motzer R.J.; Hutson T.E.; Glen H.; Michaelson M.D.; Molina A.; Eisen T.; Jassem J.; Zolnierek J.; Maroto J.P.; Mellado B.; Melichar B.; Tomasek J.; Kremer A.; Kim H.J.; Wood K.; Dutcus C.; Larkin J.; Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol  2015,16(15),1473-1482","journal-title":"Lancet Oncol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1002\/cncr.31344","volume":"124","author":"Wirth L.J.","year":"2018","unstructured":"Wirth L.J.; Tahara M.; Robinson B.; Francis S.; Brose M.S.; Habra M.A.; Newbold K.; Kiyota N.; Dutcus C.E.; Mathias E.; Guo M.; Sherman S.I.; Schlumberger M.; Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer  2018,124(11),2365-2372","journal-title":"Cancer"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"102061","DOI":"10.1016\/j.clinre.2022.102061","volume":"47","author":"Hu L.","year":"2023","unstructured":"Hu L.; Zheng Y.; Lin J.; Shi X.; Wang A.; Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol  2023,47(1),102061","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/14737140.2023.2156340","volume":"23","author":"Persano M.","year":"2023","unstructured":"Persano M.; Casadei-Gardini A.; Burgio V.; Scartozzi M.; Cascinu S.; Rimini M.; Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and\/or prognostic factors? Expert Rev Anticancer Ther  2023,23(1),19-27","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"7077","DOI":"10.1002\/cam4.5506","volume":"12","author":"Su C.W.","year":"2023","unstructured":"Su C.W.; Teng W.; Lin P.T.; Jeng W.J.; Chen K.A.; Hsieh Y.C.; Chen W.T.; Ho M.M.; Hsieh C.H.; Wang C.T.; Chai P.M.; Lin C.C.; Lin C.Y.; Lin S.M.; Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first-line treatment for unresectable hepatocellular carcinoma. Cancer Med  2023,12(6),7077-7089","journal-title":"Cancer Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1080\/14740338.2022.2153115","volume":"21","author":"Wassermann J.","year":"2022","unstructured":"Wassermann J.; Bagnis C.I.; Leenhardt L.; Ederhy S.; Buffet C.; Pre-therapeutic evaluation and practical management of cardiovascular and renal toxicities in patients with metastatic radioiodine-refractory thyroid cancer treated with lenvatinib. Expert Opin Drug Saf  2022,21(11),1401-1410","journal-title":"Expert Opin Drug Saf"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/8859826","volume":"2020","author":"Li M.","year":"2020","unstructured":"Li M.; Wang X.; Liu J.; Mao X.; Li D.; Wang Z.; Tang Y.; Wu S.; Identification of core prognosis-related candidate genes in chinese gastric cancer population based on integrated bioinformatics. BioMed Res Int  2020,2020,1-14","journal-title":"BioMed Res Int"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.2147\/IJGM.S312770","volume":"14","author":"Wang Y.","year":"2021","unstructured":"Wang Y.; Zhang M.; Gong Y.; Wu Q.; Zhang L.; Jiao S.; Bioinformatic analysis of hepatocellular carcinoma cell lines to the efficacy of nimotuzumab. Int J Gen Med  2021,14,2611-2621","journal-title":"Int J Gen Med"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.7150\/jca.25909","volume":"9","author":"Tao Y.","year":"2018","unstructured":"Tao Y.; Shan L.; Xu X.; Jiang H.; Chen R.; Qian Z.; Yang Z.; Liang B.; Zhen H.; Cai F.; Yu Y.; Ma L.; Huaier augmented the chemotherapeutic sensitivity of oxaliplatin via downregulation of yap in hepatocellular carcinoma. J Cancer  2018,9(21),3962-3970","journal-title":"J Cancer"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2174\/1573406415666191004100744","volume":"16","author":"Wang Y.","year":"2020","unstructured":"Wang Y.; Zheng B.; Xu M.; Cai S.; Younseo J.; Zhang C.; Jiang B.; Prediction and analysis of hub genes in renal cell carcinoma based on CFS gene selection method combined with adaboost algorithm. Med Chem  2020,16(5),654-663","journal-title":"Med Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.4251\/wjgo.v15.i6.1019","volume":"15","author":"Chen Y.C.","year":"2023","unstructured":"Chen Y.C.; Li D.B.; Wang D.L.; Peng H.; Comprehensive analysis of distal-less homeobox family gene expression in colon cancer. World J Gastrointest Oncol  2023,15(6),1019-1035","journal-title":"World J Gastrointest Oncol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.3390\/ijms21072496","volume":"21","author":"Lyu G.","year":"2020","unstructured":"Lyu G.; Li D.; Xiong H.; Xiao L.; Tong J.; Ning C.; Wang P.; Li S.; Quantitative proteomic analyses identify STO\/BBX24 -related proteins induced by UV-B. Int J Mol Sci  2020,21(7),2496","journal-title":"Int J Mol Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"7495","DOI":"10.15666\/aeer\/1704_74957510","author":"Li D.B.","year":"2019","unstructured":"Li D.B.; Lyu G.Z.; Lyu J.P.; Niu H.B.; Wang X.; Yin J.; Cloning and characterization of a wheat RING finger gene TaRHA2b whose expression is up-regulated by ABA treatment. Appl Ecol Environ Res  2019,7495-7510","journal-title":"Appl Ecol Environ Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"6220","DOI":"10.3390\/cancers14246220","volume":"14","author":"Yang D.","year":"2022","unstructured":"Yang D.; Liu M.; Jiang J.; Luo Y.; Wang Y.; Chen H.; Li D.; Wang D.; Yang Z.; Chen H.; Comprehensive analysis of dmrt3 as a potential biomarker associated with the immune infiltration in a pan-cancer analysis and validation in lung adenocarcinoma. Cancers  2022,14(24),6220","journal-title":"Cancers"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1179120","DOI":"10.3389\/fonc.2023.1179120","volume":"13","author":"Rui S.","year":"2023","unstructured":"Rui S.; Wang D.; Huang Y.; Xu J.; Zhou H.; Zhang H.; Prognostic value of SLC4A4 and its correlation with the microsatellite instability in colorectal cancer. Front Oncol  2023,13,1179120","journal-title":"Front Oncol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00432-024-05676-8","volume":"150","author":"Li F.","year":"2024","unstructured":"Li F.; Miao J.; Liu R.; Zhang R.; He A.; Pan-cancer analysis of DDIT4 identifying its prognostic value and function in acute myeloid leukemia. J Cancer Res Clin Oncol  2024,150(3),144","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"15919","DOI":"10.1038\/s41598-023-43174-y","volume":"13","author":"Qian B.","year":"2023","unstructured":"Qian B.; Liu Q.; Wang C.; Lu S.; Ke S.; Yin B.; Li X.; Yu H.; Wu Y.; Ma Y.; Identification of MIR600HG\/hsa-miR-342-3p\/ANLN network as a potential prognosis biomarker associated with lmmune infiltrates in pancreatic cancer. Sci Rep  2023,13(1),15919","journal-title":"Sci Rep"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.3390\/cancers15123185","volume":"15","author":"Ding Y.","year":"2023","unstructured":"Ding Y.; Wang H.; Liu J.; Jiang H.; Gong A.; Xu M.; MBD3 as a potential biomarker for colon cancer: Implications for epithelial-mesenchymal transition (EMT) pathways. Cancers  2023,15(12),3185","journal-title":"Cancers"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"23262","DOI":"10.18632\/aging.203618","volume":"13","author":"Yang Y.","year":"2021","unstructured":"Yang Y.; Gu X.; Li Z.; Zheng C.; Wang Z.; Zhou M.; Chen Z.; Li M.; Li D.; Xiang J.; Whole-exome sequencing of rectal cancer identifies locally recurrent mutations in the Wnt pathway. Aging  2021,13(19),23262-23283","journal-title":"Aging"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2147\/PGPM.S384901","volume":"15","author":"Liang W.","year":"2022","unstructured":"Liang W.; Lu Y.; Pan X.; Zeng Y.; Zheng W.; Li Y.; Nie Y.; Li D.; Wang D.; Decreased expression of a novel lncRNA FAM181A-AS1 is associated with poor prognosis and immune infiltration in lung adenocarcinoma. Pharm Genomics Pers Med  2022,15,985-998","journal-title":"Pharm Genomics Pers Med"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"p. 15330338231154091","DOI":"10.1177\/15330338231154091","volume":"22","author":"Han Q.","year":"2023","unstructured":"Han Q.; Cui Z.; Wang Q.; Pang F.; Li D.; Wang D.; Upregulation of OTX2-AS1 is associated with immune infiltration and predicts prognosis of gastric cancer. Technol Cancer Res Treat  2023,22,p. 15330338231154091","journal-title":"Technol Cancer Res Treat"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"8541","DOI":"10.2147\/IJGM.S340683","volume":"14","author":"Lin Z.","year":"2021","unstructured":"Lin Z.; Huang W.; Yi Y.; Li D.; Xie Z.; Li Z.; Ye M.; LncRNA ADAMTS9-AS2 is a prognostic biomarker and correlated with immune infiltrates in lung adenocarcinoma. Int J Gen Med  2021,14,8541-8555","journal-title":"Int J Gen Med"},{"key":"ref=39","first-page":"e934522","volume":"27","author":"Yi W.","year":"2021","unstructured":"Yi W.; Shen H.; Sun D.; Xu Y.; Feng Y.; Li D.; Wang C.; Low expression of long noncoding RNA SLC26A4 antisense RNA 1 is an independent prognostic biomarker and correlate of immune infiltrates in breast cancer. Med Sci Monit  2021,27,e934522","journal-title":"Med Sci Monit"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"e0290031","DOI":"10.1371\/journal.pone.0290031","volume":"18","author":"Chen B.","year":"2023","unstructured":"Chen B.; Lu X.; Zhou Q.; Chen Q.; Zhu S.; Li G.; Liu H.; PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer. PLoS One  2023,18(8),e0290031","journal-title":"PLoS One"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"967","DOI":"10.3892\/ijo.2017.4073","volume":"51","author":"Lee H.","year":"2017","unstructured":"Lee H.; Saini N.; Parris A.; Zhao M.; Yang X.; Ganetespib induces G2\/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling. Int J Oncol  2017,51(3),967-974","journal-title":"Int J Oncol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12033-023-00973-y","volume":"1","author":"Li Z.","year":"2023","unstructured":"Li Z.; Fan Y.; Ma Y.; Meng N.; Li D.; Wang D.; Lian J.; Hu C.; Identification of crucial genes and signaling pathways in alectinib-resistant lung adenocarcinoma using bioinformatic analysis. Mol Biotechnol  2023,1,1-6","journal-title":"Mol Biotechnol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41419-023-05919-5","volume":"14","author":"Yan Y.C.","year":"2023","unstructured":"Yan Y.C.; Meng G.X.; Yang C.C.; Yang Y.F.; Tan S.Y.; Yan L.J.; Ding Z.N.; Ma Y.L.; Dong Z.R.; Li T.; Diacylglycerol lipase alpha promotes hepatocellular carcinoma progression and induces lenvatinib resistance by enhancing YAP activity. Cell Death Dis  2023,14(7),404","journal-title":"Cell Death Dis"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1158\/0008-5472.CAN-22-0963","volume":"83","author":"Huang M.","year":"2023","unstructured":"Huang M.; Long J.; Yao Z.; Zhao Y.; Zhao Y.; Liao J.; Lei K.; Xiao H.; Dai Z.; Peng S.; Lin S.; Xu L.; Kuang M.; METTL1-mediated m7G tRNA modification promotes lenvatinib resistance in hepatocellular carcinoma. Cancer Res  2023,83(1),89-102","journal-title":"Cancer Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1080\/15548627.2022.2117893","volume":"19","author":"Pan J.","year":"2023","unstructured":"Pan J.; Zhang M.; Dong L.; Ji S.; Zhang J.; Zhang S.; Lin Y.; Wang X.; Ding Z.; Qiu S.; Gao D.; Zhou J.; Fan J.; Gao Q.; Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma. Autophagy  2023,19(4),1184-1198","journal-title":"Autophagy"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"8007","DOI":"10.1038\/s41598-022-12076-w","volume":"12","author":"He X.","year":"2022","unstructured":"He X.; Hikiba Y.; Suzuki Y.; Nakamori Y.; Kanemaru Y.; Sugimori M.; Sato T.; Nozaki A.; Chuma M.; Maeda S.; EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells. Sci Rep  2022,12(1),8007","journal-title":"Sci Rep"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/jcmm.16108","volume":"25","author":"Zhao Z.","year":"2021","unstructured":"Zhao Z.; Zhang D.; Wu F.; Tu J.; Song J.; Xu M.; Ji J.; Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS\/MEK\/ERK axis via decreasing VEGFR2 expression. J Cell Mol Med  2021,25(1),549-560","journal-title":"J Cell Mol Med"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"216742","DOI":"10.1016\/j.canlet.2024.216742","volume":"588","author":"Chen L.","year":"2024","unstructured":"Chen L.; Hu M.; Chen L.; Peng Y.; Zhang C.; Wang X.; Li X.; Yao Y.; Song Q.; Li J.; Pei H.; Targeting O-GlcNAcylation in cancer therapeutic resistance: The sugar saga continues. Cancer Lett  2024,588,216742","journal-title":"Cancer Lett"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12014-018-9194-0","volume":"15","author":"Shi F.","year":"2018","unstructured":"Shi F.; Wu H.; Qu K.; Sun Q.; Li F.; Shi C.; Li Y.; Xiong X.; Qin Q.; Yu T.; Jin X.; Cheng L.; Wei Q.; Li Y.; She J.; Identification of serum proteins AHSG, FGA and APOA-I as diagnostic biomarkers for gastric cancer. Clin Proteomics  2018,15(1),18","journal-title":"Clin Proteomics"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.yexcr.2013.12.003","volume":"321","author":"Thompson P.D.","year":"2014","unstructured":"Thompson P.D.; Sakwe A.; Koumangoye R.; Yarbrough W.G.; Ochieng J.; Marshall D.R.; Alpha-2 heremans schmid glycoprotein (AHSG) modulates signaling pathways in head and neck squamous cell carcinoma cell line SQ20B. Exp Cell Res  2014,321(2),123-132","journal-title":"Exp Cell Res"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"e878","DOI":"10.1002\/hsr2.878","volume":"5","author":"Li X.","year":"2022","unstructured":"Li X.; Ma C.; Alpha-2-heremans-schmid-glycoprotein (AHSG) a potential biomarker associated with prognosis of chromophobe renal cell carcinoma: The propolis study. Health Sci Rep  2022,5(6),e878","journal-title":"Health Sci Rep"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1158\/1055-9965.EPI-08-0696","volume":"18","author":"Yi J.K.","year":"2009","unstructured":"Yi J.K.; Chang J.W.; Han W.; Lee J.W.; Ko E.; Kim D.H.; Bae J.Y.; Yu J.; Lee C.; Yu M.H.; Noh D.Y.; Autoantibody to tumor antigen, alpha 2-HS glycoprotein: A novel biomarker of breast cancer screening and diagnosis. Cancer Epidemiol Biomarkers Prev  2009,18(5),1357-1364","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"14282","DOI":"10.1080\/21655979.2022.2081465","volume":"13","author":"Dong Y.","year":"2022","unstructured":"Dong Y.; Ding D.; Gu J.; Chen M.; Li S.; Alpha-2 heremans schmid glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF-\u03b2 signalling pathway. Bioengineered  2022,13(6),14282-14298","journal-title":"Bioengineered"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"166050","DOI":"10.1016\/j.bbadis.2020.166050","volume":"1867","author":"Das S.","year":"2021","unstructured":"Das S.; Chattopadhyay D.; Chatterjee S.K.; Mondal S.A.; Majumdar S.S.; Mukhopadhyay S.; Saha N.; Velayutham R.; Bhattacharya S.; Mukherjee S.; Increase in PPAR\u03b3 inhibitory phosphorylation by Fetuin: A through the activation of Ras-MEK-ERK pathway causes insulin resistance. Biochim Biophys Acta Mol Basis Dis  2021,1867(4),166050","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13046-022-02567-z","volume":"42","author":"Li Y.","year":"2023","unstructured":"Li Y.; Yang W.; Zheng Y.; Dai W.; Ji J.; Wu L.; Cheng Z.; Zhang J.; Li J.; Xu X.; Wu J.; Yang M.; Feng J.; Guo C.; Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. J Exp Clin Cancer Res  2023,42(1),6","journal-title":"J Exp Clin Cancer Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"154478","DOI":"10.1016\/j.phymed.2022.154478","volume":"108","author":"Chen M.Y.","year":"2023","unstructured":"Chen M.Y.; Hsu C.H.; Setiawan S.A.; Tzeng D.T.W.; Ma H.P.; Ong J.R.; Chu Y.C.; Hsieh M.S.; Wu A.T.H.; Tzeng Y.M.; Yeh C.T.; Ovatodiolide and antrocin synergistically inhibit the stemness and metastatic potential of hepatocellular carcinoma via impairing ribosome biogenesis and modulating ERK\/Akt-mTOR signaling axis. Phytomedicine  2023,108,154478","journal-title":"Phytomedicine"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1053\/j.gastro.2012.05.050","volume":"143","author":"Mart\u00ednez-L\u00f3pez N.","year":"2012","unstructured":"Mart\u00ednez-L\u00f3pez N.; Garc\u00eda-Rodr\u00edguez J.L.; Varela-Rey M.; Guti\u00e9rrez V.; Fern\u00e1ndez-Ramos D.; Beraza N.; Aransay A.M.; Schlangen K.; Lozano J.J.; Aspichueta P.; Luka Z.; Wagner C.; Evert M.; Calvisi D.F.; Lu S.C.; Mato J.M.; Mart\u00ednez-Chantar M.L.; Hepatoma cells from mice deficient in glycine N-methyltransferase have increased RAS signaling and activation of liver kinase B1. Gastroenterology  2012,143(3),787-798.e13","journal-title":"Gastroenterology"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"101835","DOI":"10.1016\/j.clinre.2021.101835","volume":"46","author":"Liu T.","year":"2022","unstructured":"Liu T.; Yuan Z.; Wang H.; Wang J.; Xue L.; Peroxisome-related genes in hepatocellular carcinoma correlated with tumor metabolism and overall survival. Clin Res Hepatol Gastroenterol  2022,46(10),101835","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"10899","DOI":"10.1002\/jcp.27905","volume":"234","author":"Wang C.","year":"2019","unstructured":"Wang C.; Yang M.; Zhao J.; Li X.; Xiao X.; Zhang Y.; Jin X.; Liao M.; Bile salt (glycochenodeoxycholate acid) induces cell survival and chemoresistance in hepatocellular carcinoma. J Cell Physiol  2019,234(7),10899-10906","journal-title":"J Cell Physiol"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673329991241111111941","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/238607\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0109298673329991241111111941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T04:20:43Z","timestamp":1760674843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/238607\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":59,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0109298673329991241111111941","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}